In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

He said GSK was not trying to beat the biggest players in oncology. Instead, the company was focusing its oncology business on creating drugs for seriously ill patients who do not respond to other ...

Drugmaker GSK has today reaffirmed its outlook for 2025 and said it was "well positioned" to mitigate any hit from potential sector-specific tariffs, after first quarter results beat expectations.

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.

GSK says it will support its partners with education and adoption of new sustainability measures. In October, meanwhile, GSK will summon more than 160 suppliers to hash out strategies for its ...